Gamida Cell has upped its financing by $40 million in its latest funding round to prep for final work on a late-stage stem cell blood cancer therapy.

Sean Parker’s immuno-oncology institute has allied with Tessa Therapeutics to turn T-cell therapies against solid tumors.

An Ernst & Young report shows a mixed bag across the whole sector.

Bavarian Nordic has again delayed the release of data from a phase 3 trial of Prostvac.

J&J has unveiled another clutch of deals and collaborations with industry and academia.

Probably hoping to help turn things around after clinical setbacks, microRNA biotech Regulus tapped the help of CRO Aptuit.

Jeffrey Kindler’s Centrexion Therapeutics has posted six-month data from a phase 2b trial of its nonopioid treatment for knee pain.

Celgene has published data showing its drug has “positive trends” in lupus.

Orum Therapeutics has raised a small series A to help push on with its work on a monoclonal antibody designed to treat undruggable cytosolic targets.

A phase 2b trial of Aldeyra Therapeutics’ allergic conjunctivitis candidate ADX-102 has missed its primary endpoint.

R&D